GlassScriptPhysician profile
Christopher J Roberson
NPI 1184064941
$180,213.09
in general payments reported to CMS, 2019-2025
13 companies · $71K in 2025
The $71K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,189 · 2022: $19K · 2023: $26K · 2024: $57K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $109K · Travel and Lodging: $23K · Food and Beverage: $15K · Consulting Fee: $6,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $108,882.50 |
| Travel and Lodging | $23,420.74 |
| Food and Beverage | $15,049.56 |
| Consulting Fee | $6,610.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $119,220.86 | 2021-2025 | Descovy, Biktarvy, Yeztugo |
| Viiv Healthcare Company | $57,251.61 | 2021-2025 | Cabenuva, Apretude, Dovato |
| Merck Sharp & Dohme LLC | $1,923.89 | 2021-2025 | Pifeltro, Isentress, Delstrigo |
| Abbvie INC. | $730.67 | 2022-2025 | |
| Janssen Products, LP | $381.70 | 2021-2022 | |
| Abbott Laboratories | $224.60 | 2025 | Aveir |
| Janssen Biotech, INC. | $134.60 | 2021-2023 | Symtuza |
| Napo Pharmaceuticals INC | $133.21 | 2023 | Mytesi |
| Exact Sciences Corporation | $77.29 | 2023-2025 | Cologuard Collection Kit |
| Melinta Therapeutics, LLC | $69.63 | 2023 | Rezzayo |
| Astrazeneca Pharmaceuticals LP | $25.18 | 2021 | |
| Pfizer INC. | $22.00 | 2022 | |
| Novo Nordisk INC | $17.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.